Lyell Immunopharma, Inc.
LYEL· Nasdaq
LYELLyell Immunopharma, Inc.
Filed Nov 12, 2021 · 10-Q · 43 days after period end · 0000950170-21-004270
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Revenue | $2.76M | $1.07M |
| Net Income | -$48.88M | -$35.72M |
| EPS Diluted | -$0.20 | -$2.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end
